The generic drug race isn’t just about science—it’s about timing, leverage, and who wins the “first shot.”
If you’ve ever wondered why some generic launches feel like they happen overnight while others drag on for years, the answer is often hiding in…

Specialty pharmacy contracts don’t wait for patents to expire. Neither should your strategy.
In biopharma, the most expensive mistake isn’t missing a launch date—it’s arriving too late to the commercial plumbing that determines whether patients actuall…

The internet keeps asking: “Can this drug do that?” The pharmacology keeps sighing.
Every week, another thread goes viral: “Wait—if this medication helps with X, why can’t it treat Y?” The question is understandable. The logic feels intuitive. If a d…

Stop the DIY Patent Search: The FTO Opinion That Could Save You From “Willful” Infringement
Most companies treat freedom-to-operate (FTO) like a box-checking exercise: run a quick patent search, skim a few claims, and move on. It feels efficient. It fe…

Stop the DIY Patent Search: The FTO Opinion That Could Save You From “Willful” Infringement
In pharma, the most expensive mistake is often the one you don’t realize you made—because you thought you were being careful.
A growing number of companies are …

Pharma procurement teams don’t buy “a drug.” They buy a lifetime of costs.
Most organizations still treat drug purchasing like a one-line transaction: unit price in, inventory out, done. But the real economics of a therapy don’t stop at the invoice. …

Pharma doesn’t just invent drugs—it also buys time.
In the race to recoup R&D costs, “extra time” can be worth billions. And nowhere is that more visible than in drug patent term extensions—an increasingly central strategy in how Big Pharma prote…

Cosentyx, a medication for multiple sclerosis, psoriasis, and psoriatic arthritis, works by blocking a protein called IL-17A…. https://www.Drugchatter.com/chat/20292/how-often-should-i-adjust-cosentyx/